Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
This is a phase II, open label, non-randomized study in patients with
histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage
IV NSCLC who have not received prior chemotherapy. The trial will evaluate the efficacy and
safety profile of the combination of docetaxel, carboplatin and cetuximab for patients with
advanced NSCLC.
Patients will receive a combination of docetaxel and carboplatin administered every 3 weeks
plus cetuximab given weekly. A maximum of four cycles of chemotherapy will be administered
to patients. Patients who demonstrate an ongoing response (CR/PR/SD) at the end of 4th
cycle of chemotherapy, may receive two more cycles of treatment. Patients who continue to
respond (CR/PR/SD) after six cycles of therapy may receive therapy with single agent
cetuximab (250 mg/m2/week) for up to 1 year or until disease progression or unacceptable
toxicity, whichever occurs first.
Patients will be evaluated for response, time to progression, and overall survival. In
addition, the safety profile of the combination will be assessed.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Chandra Belani, MD
Principal Investigator
Veeda Oncology
United States: Food and Drug Administration
I-04-002
NCT00251498
October 2007
Name | Location |
---|---|
Veeda Oncology | Houston, Texas 77042 |